Evidence map›Paper›PMID 34009568›Full record

ArticleMolecular biology reports2021

Expression profiles of Natural Killer Group 2D Ligands (NGK2DLs) in colorectal carcinoma and changes in response to chemotherapeutic agents.

Burak Kucuk, Esra Yilmaz, Ercan Cacan

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Associations between MICA and MICB Genetic Variants, Protein Levels, and Colorectal Cancer: Atherosclerosis Risk in Communities (ARIC).Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Burak KucukDepartment of Molecular Biology and Genetics, Tokat Gaziosmanpasa University, 60250, Tokat, Turkey.ORCID http://orcid.org/0000-0002-9325-2359
Esra YilmazDepartment of Molecular Biology and Genetics, Tokat Gaziosmanpasa University, 60250, Tokat, Turkey.ORCID http://orcid.org/0000-0002-9922-8341
Ercan CacanDepartment of Molecular Biology and Genetics, Tokat Gaziosmanpasa University, 60250, Tokat, Turkey. ercan.cacan@gop.edu.tr.ORCID http://orcid.org/0000-0002-3487-9493
Tokat Gaziosmanpaşa Üniversitesi · TR

Funding

Tokat Gaziosmanpasa University, Scientific Research Projects 2019/15
6 · The paper itself

Abstract

Colorectal cancer (CRC) is one of the most common cancers worldwide. Natural Killer Group 2D Receptor (NKG2D) and their ligands (NKG2DLs) play crucial roles in natural killer (NK) cell-mediated cytotoxicity. Tumorigeneses cause increased NKG2DLs expression on tumor cell surfaces, thereby these cells individually eliminated by NK cells. However, CRC cells can reduce their NKG2DL expression to escape from NK-mediated immune surveillance which is associated with poor prognosis. Therefore, previous studies suggest that up-regulation of NKG2DLs can contribute to promising NK cell-mediated immunotherapy strategies. We aimed to analyze NKG2DLs expression profiles in response to chemotherapeutic drugs and increased MHC class I polypeptide-related sequence A (MICA) expression, which is related to favorable prognosis in CRC, using low doses of bortezomib and epirubicin combination without causing direct cytotoxicity. Results showed that MICA expression  sligthly increased following drug treatment in the CRC cells but not for the normal cells. Also, we enriched our study with Gene Expression Omnibus (GEO) datasets including expression profiles of various NKG2DLs using in silico analyses. Accordingly, NKG2DL expression in CRC was screened in proportion to other cancers, histologic subtypes, TNM stages and metastatic samples to compare with our data. Overall, the analyzed data showed that NKG2DLs demonstrate different expression profiles in response to chemotherapeutic agents and a combination of low-dose bortezomib and epirubicin slightly increased MICA mRNA expression in CRC cell lines. However, performing further analysis of the combination therapy for MICA protein expression and studying its interaction with NK cells will make the results more meaningful.

Indexed as

Antineoplastic AgentsBortezomibCell Line, TumorColorectal NeoplasmsDatabases, GeneticEpirubicinGene ExpressionHistocompatibility Antigens Class IHumansImmunotherapyKiller Cells, NaturalLigandsLymphocyte ActivationNK Cell Lectin-Like Receptor Subfamily KReceptors, Natural Killer CellTranscriptomeAntineoplastic AgentsBortezomibEpirubicinHistocompatibility Antigens Class IKLRK1 protein, humanLigandsNK Cell Lectin-Like Receptor Subfamily KReceptors, Natural Killer CellBortezomibColorectal cancerEpirubicinImmunotherapyMICANKG2DL

Identifiers

PMID34009568
OpenAlexW3160905972

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.